Earnings call transcript: NVE Corporation Q4 2026 earnings show strong growth

NVE Corporation reported Q4 revenue of $7.65 million, up 5% year over year, with net income rising 27% to $4.9 million, or $1.02 per diluted share. The beat was driven by a 34% surge in non-defense product sales that offset a 79% drop in defense sales, while operating expenses fell 19% and the company completed a major manufacturing expansion that doubled capacity. Shares rose 3.99% in aftermarket trading to $88.37, near the 52-week high of $88.86, as management sounded optimistic on future demand and growth.

Analysis

NVEC’s quarter is less a one-off beat than evidence that its mix is shifting toward a higher-quality, more durable revenue base: non-defense demand is now doing the heavy lifting while the defense line remains lumpy. The key second-order effect is leverage from the manufacturing expansion just as the company is carrying more inventory and converting more of the R&D stack into production; that combination can translate into outsized incremental margins for the next few quarters if order flow stays intact. Investors should also note the tax step-down is partly transitory, so the market may be underestimating the durability of reported EPS if it extrapolates the current run-rate without normalizing credits.

The bigger medium-term catalyst is not the quarter itself but the capacity inflection meeting secular end-market exposure: medical devices, robotics, and industrial automation tend to reward tiny, reliable components with long design cycles, which can create a slow but sticky ramp after initial wins. That makes the setup asymmetric over 6-12 months: if new product adoption converts even modestly, the expanded fab should drive operating leverage without a matching step-up in SG&A. The main risk is that defense and contract R&D remain too volatile to model cleanly, so any disappointment there can mask continued core product strength and compress the multiple quickly.

Contrary to the immediate price reaction, the opportunity may be less about chasing a breakout and more about owning the post-capex earnings inflection before consensus resets upward. The market is likely anchoring on the recent high and treating the move as a crowded quality-smalls re-rate, but the more important variable is whether management can sustain product growth with lower CapEx and still preserve premium margins. If that happens, the stock can compound on both earnings and multiple, while any slowdown would likely show up first as a fading of order momentum rather than a margin collapse.

Key Decisions for Investors

• Initiate a starter long NVEC position over the next 1-2 sessions; target 6-12 months with upside driven by operating leverage from the newly completed capacity expansion. Use a tight risk budget: if product revenue growth decelerates for two consecutive quarters, trim 50% as the market will likely de-rate the multiple quickly.
• Buy NVEC 3-6 month call spreads rather than outright stock for asymmetric exposure to a capacity-led re-rating; structure around strikes near the recent high to reduce premium bleed. Best for investors who want upside participation with defined downside.
• Pair trade: long NVEC / short TXN on a 1-3 month horizon. The thesis is that NVEC has more near-term earnings inflection from niche product adoption, while TXN remains exposed to broader analog cyclicality; this isolates company-specific momentum rather than macro beta.
• If already long NVEC, sell covered calls against strength into the 52-week high area to monetize elevated sentiment while preserving core exposure. The stock appears closer to a tactical resistance zone than a fundamental ceiling, so income capture is favorable here.
• Set a catalyst watch for the next two quarters: if defense sales and contract R&D stabilize while non-defense growth stays above the low-20s, add on pullbacks. If not, reduce exposure before the market starts pricing the CapEx spend as under-earning capacity.